Starlynn Clarke

Starlynn Clarke has an extensive work experience in the field of biology and molecular research. Starlynn currently holds the position of Director, Preclinical Biology at Rondo Therapeutics, where they started in 2023. Prior to this role, they worked as a Senior Scientist II, Preclinical Biology at the same company from May 2022 to January 2023.

Before joining Rondo Therapeutics, Starlynn worked at Frontier Medicines as a Senior Scientist, Disease Biology from July 2021 to April 2022, and as a Scientist, Disease Biology from March 2020 to July 2021. Starlynn also gained experience as a Scientist at Caribou Biosciences from May 2019 to March 2020.

Starlynn's earlier experience includes roles at Teneobio, Inc., where they worked as a Research Scientist III, Preclinical Development from January 2019 to May 2019, as a Research Scientist II, Preclinical Development from October 2016 to December 2018, and as a Research Scientist I, Preclinical Development from October 2015 to October 2016.

Starlynn obtained their Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco, where they conducted research on viral and fungal pathogens and their interactions with host proteins. Starlynn completed their Ph.D. from September 2009 to September 2015.

In addition to their research roles, Starlynn has experience in teaching as an Adjunct Faculty at the University of San Francisco from August 2013 to May 2015. Starlynn taught laboratory courses in Introductory General Biology and Genetics.

Starlynn's earliest research experience dates back to their undergraduate years at UC Irvine, where they worked as an Undergraduate Researcher in two different laboratories. Starlynn studied disease concordance and inheritance patterns in families with Celiac disease in a genetics laboratory and explored the effects of in utero exposure to organotins on weight and metabolism in a cellular biology laboratory. Starlynn worked in these roles from September 2007 to March 2009.

Starlynn also gained research experience as an Amgen Scholar at Stanford University, where they conducted summer research on major histocompatibility complex class-II peptide binding from June 2008 to August 2008.

Starlynn Clarke completed their Bachelor of Science (B.S.) degree in Genetics from UC Irvine from 2006 to 2009. Starlynn then pursued their education further and obtained a Doctor of Philosophy (PhD) degree in Biochemistry and Molecular Biology from the University of California, San Francisco, completing their studies from 2009 to 2015.